<?xml version='1.0' encoding='utf-8'?>
<document id="20450099"><sentence text="[Antiepileptic drugs in North America]." /><sentence text="In this review study, second-generation antiepileptic drugs (AEDs) (levetiracetam, gabapentin, topiramate, lamotrigine, zonisamide, oxcarbazepine, vigabatrin, pregabalin, rufinamide, tiagabine, lacosamide, and felbamate) and injectable AEDs (levetiracetam, lacosamide, fosphenytoin, lorazepam, and valproic acid) available in North America were compared with those available in Japan"><entity charOffset="68-81" id="DDI-PubMed.20450099.s2.e0" text="levetiracetam" /><entity charOffset="83-93" id="DDI-PubMed.20450099.s2.e1" text="gabapentin" /><entity charOffset="95-105" id="DDI-PubMed.20450099.s2.e2" text="topiramate" /><entity charOffset="107-118" id="DDI-PubMed.20450099.s2.e3" text="lamotrigine" /><entity charOffset="120-130" id="DDI-PubMed.20450099.s2.e4" text="zonisamide" /><entity charOffset="132-145" id="DDI-PubMed.20450099.s2.e5" text="oxcarbazepine" /><entity charOffset="147-157" id="DDI-PubMed.20450099.s2.e6" text="vigabatrin" /><entity charOffset="159-169" id="DDI-PubMed.20450099.s2.e7" text="pregabalin" /><entity charOffset="171-181" id="DDI-PubMed.20450099.s2.e8" text="rufinamide" /><entity charOffset="183-192" id="DDI-PubMed.20450099.s2.e9" text="tiagabine" /><entity charOffset="194-204" id="DDI-PubMed.20450099.s2.e10" text="lacosamide" /><entity charOffset="210-219" id="DDI-PubMed.20450099.s2.e11" text="felbamate" /><entity charOffset="242-255" id="DDI-PubMed.20450099.s2.e12" text="levetiracetam" /><entity charOffset="257-267" id="DDI-PubMed.20450099.s2.e13" text="lacosamide" /><entity charOffset="269-281" id="DDI-PubMed.20450099.s2.e14" text="fosphenytoin" /><entity charOffset="283-292" id="DDI-PubMed.20450099.s2.e15" text="lorazepam" /><entity charOffset="298-311" id="DDI-PubMed.20450099.s2.e16" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e0" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e1" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e2" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e3" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e4" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e5" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e6" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e6" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e7" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e7" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e8" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e8" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e9" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e9" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e10" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e10" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e11" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e11" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e12" e2="DDI-PubMed.20450099.s2.e12" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e12" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e12" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e12" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e12" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e13" e2="DDI-PubMed.20450099.s2.e13" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e13" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e13" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e13" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e14" e2="DDI-PubMed.20450099.s2.e14" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e14" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e14" e2="DDI-PubMed.20450099.s2.e16" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e15" e2="DDI-PubMed.20450099.s2.e15" /><pair ddi="false" e1="DDI-PubMed.20450099.s2.e15" e2="DDI-PubMed.20450099.s2.e16" /></sentence><sentence text=" Three second-generation AEDs (gabapentin, topiramate, and lamotrigine) were recently approved in Japan"><entity charOffset="31-41" id="DDI-PubMed.20450099.s3.e0" text="gabapentin" /><entity charOffset="43-53" id="DDI-PubMed.20450099.s3.e1" text="topiramate" /><entity charOffset="59-70" id="DDI-PubMed.20450099.s3.e2" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.20450099.s3.e0" e2="DDI-PubMed.20450099.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s3.e0" e2="DDI-PubMed.20450099.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s3.e0" e2="DDI-PubMed.20450099.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s3.e1" e2="DDI-PubMed.20450099.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s3.e1" e2="DDI-PubMed.20450099.s3.e2" /></sentence><sentence text=" Levetiracetam is currently under review for approval by the Japanese regulatory agency"><entity charOffset="1-14" id="DDI-PubMed.20450099.s4.e0" text="Levetiracetam" /></sentence><sentence text=" An ideal AED would have a broad-spectrum activity to control multiple types of seizures, favorable safety profile, limited potential for drug-drug interaction, many bioequivalent formulations, long half life to allow infrequent administration, and antiepileptogenic effects that may provide a fundamental cure of epileptic patients by suppressing the development of epileptogenic network and neutralizing previously established epileptogenic foci in the brain" /><sentence text=" The second-generation AEDs have been developed to possess some of these ideal properties" /><sentence text=" All the second-generation AEDs are efficacious for the treatment of patients with partial seizures" /><sentence text=" In addition, levetiracetam, topiramate, lamotrigine, and zonisamide are effective for the treatment of patients with generalized tonic-clonic seizures, absences, myoclonic seizures, Lennox-Gastaut syndrome, and West syndrome; however, lamotrigine is not effective for the treatment of patients with myoclonic seizures"><entity charOffset="14-27" id="DDI-PubMed.20450099.s8.e0" text="levetiracetam" /><entity charOffset="29-39" id="DDI-PubMed.20450099.s8.e1" text="topiramate" /><entity charOffset="41-52" id="DDI-PubMed.20450099.s8.e2" text="lamotrigine" /><entity charOffset="58-68" id="DDI-PubMed.20450099.s8.e3" text="zonisamide" /><entity charOffset="236-247" id="DDI-PubMed.20450099.s8.e4" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e0" e2="DDI-PubMed.20450099.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e0" e2="DDI-PubMed.20450099.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e0" e2="DDI-PubMed.20450099.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e0" e2="DDI-PubMed.20450099.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e0" e2="DDI-PubMed.20450099.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e1" e2="DDI-PubMed.20450099.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e1" e2="DDI-PubMed.20450099.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e1" e2="DDI-PubMed.20450099.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e1" e2="DDI-PubMed.20450099.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e2" e2="DDI-PubMed.20450099.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e2" e2="DDI-PubMed.20450099.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e2" e2="DDI-PubMed.20450099.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e3" e2="DDI-PubMed.20450099.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s8.e3" e2="DDI-PubMed.20450099.s8.e4" /></sentence><sentence text=" Rufinamide and felbamate are useful for the treatment of patients with Lennox-Gastaut syndrome; however owing to its serious adverse effects, including aplastic anemia and hepatic failure, felbamate is used as the last resort for the treatment of patients with intractable seizures"><entity charOffset="1-11" id="DDI-PubMed.20450099.s9.e0" text="Rufinamide" /><entity charOffset="16-25" id="DDI-PubMed.20450099.s9.e1" text="felbamate" /><entity charOffset="190-199" id="DDI-PubMed.20450099.s9.e2" text="felbamate" /><pair ddi="false" e1="DDI-PubMed.20450099.s9.e0" e2="DDI-PubMed.20450099.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s9.e0" e2="DDI-PubMed.20450099.s9.e1" /><pair ddi="true" e1="DDI-PubMed.20450099.s9.e0" e2="DDI-PubMed.20450099.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s9.e1" e2="DDI-PubMed.20450099.s9.e1" /><pair ddi="true" e1="DDI-PubMed.20450099.s9.e1" e2="DDI-PubMed.20450099.s9.e2" /></sentence><sentence text=" Vigabatrin is particularly effective for the treatment of patients with West syndrome; however, the patients need to be regularly monitored for the development of peripheral visual field defect"><entity charOffset="1-11" id="DDI-PubMed.20450099.s10.e0" text="Vigabatrin" /></sentence><sentence text=" Gabapentin, oxcarbazepine, vigabatrin, and tiagabine are ineffective for the treatment of patients with absences and/or myoclonic seizures and may aggravate these conditions"><entity charOffset="1-11" id="DDI-PubMed.20450099.s11.e0" text="Gabapentin" /><entity charOffset="13-26" id="DDI-PubMed.20450099.s11.e1" text="oxcarbazepine" /><entity charOffset="28-38" id="DDI-PubMed.20450099.s11.e2" text="vigabatrin" /><entity charOffset="44-53" id="DDI-PubMed.20450099.s11.e3" text="tiagabine" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e0" e2="DDI-PubMed.20450099.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e0" e2="DDI-PubMed.20450099.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e0" e2="DDI-PubMed.20450099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e0" e2="DDI-PubMed.20450099.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e1" e2="DDI-PubMed.20450099.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e1" e2="DDI-PubMed.20450099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e1" e2="DDI-PubMed.20450099.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e2" e2="DDI-PubMed.20450099.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s11.e2" e2="DDI-PubMed.20450099.s11.e3" /></sentence><sentence text=" Treatment with levetiracetam or topiramate (off-label use) is the new option for patients with refractory status epilepticus, which is characterized by downregulation of the inhibitory gamma-aminobutyric acid system, because these drugs act via different mechanisms and are rapidly titratable, especially intravenous levetiracetam"><entity charOffset="16-29" id="DDI-PubMed.20450099.s12.e0" text="levetiracetam" /><entity charOffset="33-43" id="DDI-PubMed.20450099.s12.e1" text="topiramate" /><entity charOffset="186-209" id="DDI-PubMed.20450099.s12.e2" text="gamma-aminobutyric acid" /><entity charOffset="318-331" id="DDI-PubMed.20450099.s12.e3" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e0" e2="DDI-PubMed.20450099.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e0" e2="DDI-PubMed.20450099.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e0" e2="DDI-PubMed.20450099.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e0" e2="DDI-PubMed.20450099.s12.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e1" e2="DDI-PubMed.20450099.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e1" e2="DDI-PubMed.20450099.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e1" e2="DDI-PubMed.20450099.s12.e3" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e2" e2="DDI-PubMed.20450099.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s12.e2" e2="DDI-PubMed.20450099.s12.e3" /></sentence><sentence text=" The pharmacokinetic profiles of levetiracetam, gabapentin, and pregabalin are favorable: these drugs exhibit minimal protein binding, do not undergo hepatic metabolism, are not involved in any clinically relevant drug interactions, and rarely lead to the development of serious adverse effects"><entity charOffset="33-46" id="DDI-PubMed.20450099.s13.e0" text="levetiracetam" /><entity charOffset="48-58" id="DDI-PubMed.20450099.s13.e1" text="gabapentin" /><entity charOffset="64-74" id="DDI-PubMed.20450099.s13.e2" text="pregabalin" /><pair ddi="false" e1="DDI-PubMed.20450099.s13.e0" e2="DDI-PubMed.20450099.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s13.e0" e2="DDI-PubMed.20450099.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s13.e0" e2="DDI-PubMed.20450099.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20450099.s13.e1" e2="DDI-PubMed.20450099.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20450099.s13.e1" e2="DDI-PubMed.20450099.s13.e2" /></sentence><sentence text=" In general, levetiracetam is probably the closest to being the ideal AED because of its broad-spectrum favorable pharmacokinetic profile and safety profile as well as because of the availability of its parenteral formulation"><entity charOffset="13-26" id="DDI-PubMed.20450099.s14.e0" text="levetiracetam" /></sentence><sentence text=" Among the injectable AEDs, fosphenytoin is a water-soluble prodrug and is used to treat patients with status epilepticus"><entity charOffset="28-40" id="DDI-PubMed.20450099.s15.e0" text="fosphenytoin" /></sentence><sentence text=" Systemic and local side effects of this drug are fewer than those of phenytoin"><entity charOffset="70-79" id="DDI-PubMed.20450099.s16.e0" text="phenytoin" /></sentence><sentence text=" Lorazepam, a benzodiazepine is used as the first-line AED for the treatment of patients with status epilepticus"><entity charOffset="1-10" id="DDI-PubMed.20450099.s17.e0" text="Lorazepam" /><entity charOffset="14-28" id="DDI-PubMed.20450099.s17.e1" text="benzodiazepine" /><pair ddi="false" e1="DDI-PubMed.20450099.s17.e0" e2="DDI-PubMed.20450099.s17.e0" /><pair ddi="false" e1="DDI-PubMed.20450099.s17.e0" e2="DDI-PubMed.20450099.s17.e1" /></sentence><sentence text=" The effects of this drug are more prolonged than those of diazepam"><entity charOffset="59-67" id="DDI-PubMed.20450099.s18.e0" text="diazepam" /></sentence><sentence text=" Intravenous administration of valproic acid is regarded as a new treatment option for patients with status epilepticus, because sedative and negative effects on the cardiorespiratory system of this drug are lesser than those of the traditional injectable AEDs"><entity charOffset="31-44" id="DDI-PubMed.20450099.s19.e0" text="valproic acid" /></sentence><sentence text=" These novel medications will aid the improvement of the quality of life of epileptic patients through improved seizure control and reduced adverse effects" /><sentence text="" /></document>